Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.
Saved in:
| Title: | Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. |
|---|---|
| Authors: | Wu, Yi-Long (AUTHOR), Xu, Chong-Rui (AUTHOR), Hu, Cheng-Ping (AUTHOR), Feng, Jifeng (AUTHOR), Lu, Shun (AUTHOR), Huang, Yunchao (AUTHOR), Li, Wei (AUTHOR), Hou, Mei (AUTHOR), Shi, Jian Hua (AUTHOR), Märten, Angela (AUTHOR), Fan, Jean (AUTHOR), Peil, Barbara (AUTHOR), Zhou, Caicun (AUTHOR) |
| Source: | OncoTargets & Therapy. Nov2018, Vol. 11, p8575-8587. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 11786930 |
|---|---|
| DOI: | 10.2147/OTT.S160358 |
